Top Stories
Intellia lonvo-z becomes first in vivo CRISPR therapy to succeed in Phase 3, initiating rolling FDA submission for hereditary angioedema
On April 27, 2026, Intellia Therapeutics announced that lonvoguran ziclumeran (lonvo-z) met its primary endpoint in the global Phase 3 HAELO trial for hereditary angioedema (HAE), becoming the first in vivo gene editing therapy to succeed at the pivotal stage, according to Endpoints News. The therapy uses CRISPR to knock down the KLKB1 gene encoding plasma kallikrein directly in the liver after a single intravenous dose. A single dose of lonvo-z reduced HAE attack rates by 87% compared to placebo over approximately six months, with monthly attacks averaging 0.26 versus 2.10 in the placebo group; 62% of lonvo-z recipients were attack-free or required no additional therapy during the observation period, compared to 11% of placebo patients, according to Intellia investor relations. The most common treatment-emergent adverse events were infusion-related reactions, headache, and fatigue, with no serious adverse events observed in the lonvo-z arm as of the data cutoff (February 10, 2026). Intellia has initiated a rolling BLA submission to the FDA, with completion expected in the second half of 2026 and a potential US launch in the first half of 2027. As Fierce Biotech reported, the efficacy picture is compelling, though durability of KLKB1 knockdown beyond the trial observation window and long-term off-target safety monitoring remain open questions for label negotiations and payer contracting.
Gene therapy leaders aim to scale bespoke CRISPR treatments under FDA's plausible mechanism pathway following Baby KJ precedent
Nearly a year after Baby KJ Muldoon received the first-ever personalized CRISPR treatment for carbamoyl-phosphate synthetase 1 (CPS1) deficiency — a severe, often fatal ultra-rare inborn error of immunity — researchers at the Innovative Genomics Institute are preparing to treat another child with a different genetic disease using the same bespoke approach, as reported by BioSpace. The effort is enabled by the FDA's "plausible mechanism pathway," a novel regulatory framework outlined by FDA officials Vinay Prasad and Martin Makary that allows individualized gene editing therapies to advance based on mechanistic evidence — such as mouse models demonstrating successful editing in 42% of liver cells in Baby KJ's case — rather than requiring traditional large-scale clinical trials. Aurora Therapeutics, co-founded by CRISPR co-inventor Jennifer Doudna and genetic medicine expert Fyodor Urnov with $16 million in seed funding from Menlo Ventures, intends to develop multiple gene editing treatments for rare conditions simultaneously using this pathway, starting with phenylketonuria (PKU), according to BioPharma Dive. The pathway has implications for an estimated 300 million patients worldwide with rare genetic disorders where traditional clinical trial enrollment is impractical due to extremely small patient populations. The framework represents a structural regulatory shift that could materially expand the addressable scope of gene therapy development in rare disease.
Pipeline Watch
Aurora Therapeutics, co-founded by Jennifer Doudna and Fyodor Urnov and seeded with $16M from Menlo Ventures, is advancing phenylketonuria (PKU) as its first target under the FDA's plausible mechanism pathway, according to BioPharma Dive. Led by biotech veteran Ed Kaye, the company intends to develop multiple bespoke gene editing treatments simultaneously for rare conditions where traditional clinical trials are impractical. The PKU program will serve as a test case for whether the regulatory framework can support scalable development of individualized therapies.
Competitive Landscape
The lonvo-z Phase 3 success positions in vivo CRISPR as a third modality in HAE prophylaxis alongside subcutaneous biologics and oral agents. HAE affects an estimated 8,700 to 9,600 diagnosed patients in the US based on claims-based prevalence data. Pricing, durability, and payer willingness to reimburse a one-time intervention versus established chronic options — which carry annual wholesale acquisition costs in the $500,000–$630,000 range based on current WAC pricing — remain open variables that will define how market share evolves. Approved gene therapies including Zolgensma and Hemgenix have established one-time pricing precedents in the $2.1M–$3.5M range based on publicly announced pricing, with outcomes-based installment structures; lonvo-z will likely require a similar contracting framework, though higher HAE patient numbers relative to ultra-rare conditions create both scale opportunity and negotiating complexity for market access teams.
| Company / Product | Modality | Regulatory Status | Approx Annual WAC |
|---|---|---|---|
| Intellia / lonvo-z | In Vivo CRISPR (KLKB1 knockdown) | Rolling BLA Submission | TBD (one-time) |
| Takeda / Takhzyro (lanadelumab) | Subcutaneous Biologic | FDA Approved | ~$534K/yr (Q2W dosing) |
| BioCryst / Orladeyo (berotralstat) | Oral Plasma Kallikrein Inhibitor | FDA Approved | ~$630K/yr (based on current WAC) |
| Pharming / Ruconest (C1-INH) | IV Enzyme Replacement (acute) | FDA Approved | Per-attack dosing |
A validated in vivo CRISPR mechanism for a rare liver-expressed target creates a reference for other hepatic gene therapy and editing programs. AAV-based gene therapies and RNA interference approaches in liver targets such as TTR amyloidosis may face increased scrutiny on their relative durability and safety profiles as the in vivo editing framework matures.
Forward Looking
- FDA acceptance of the lonvo-z rolling submission and assignment of a PDUFA date will be the next sequential catalyst; advisory committee scope and off-target safety data requirements will signal regulatory posture toward in vivo CRISPR as a class.
- Durability data from lonvo-z long-term follow-up cohorts will be foundational for payer contracting; outcomes-based installment structures and rebate triggers tied to sustained attack reduction are a likely negotiating framework for market access teams to model.
- Aurora Therapeutics' progress toward IND-enabling studies for PKU using the plausible mechanism pathway will be a key signal of whether bespoke gene editing can scale beyond individual compassionate-use cases into a reproducible regulatory and commercial framework for ultra-rare genetic diseases.